Heart drug entresto may double as diabetes treatment, small study hints
NCT ID NCT03508739
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a heart failure medication called Entresto (sacubitril/valsartan) can boost a natural hormone that helps control blood sugar after meals. Researchers will give the drug or a comparison drug (valsartan) to 25 adults with type 2 diabetes or prediabetes and high blood pressure. They will measure levels of GLP-1, insulin, and glucose after a meal to see if Entresto improves sugar metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacubitril/Valsartan (Entresto) and Valsartan (Diovan)
What this could lead to
If successful, this could point toward a new way to treat type 2 diabetes by using an existing heart failure medication to improve blood sugar control.
What could go wrong
This is a small, early-phase study that is currently suspended, so results are uncertain. It only tests short-term effects on hormone levels, not long-term diabetes outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States